Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Weaning HFNC: When to Stop High-Flow Oxygen in Acute Respiratory Failure

Official title: Effect of High Flow Nasal Therapy (HFNC) Weaning Protocols vs Standard of Care on Respiratory Outcomes in Patients With Acute Respiratory Failure: A Randomized Clinical Trial

Run by University of Milan · NCT07638293 · Data updated 2026-11-12

This study tests a protocol to guide when to stop high-flow nasal therapy in adults with acute respiratory failure who are already on HFNC.

More Acute Respiratory Failure (ARF) trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment148 (estimated)
SponsorUniversity of Milan
Academic / other
Locations2 sites (Milan, Lombardy and 1 other locations)
StatusRecruiting
StartedMay 15, 2026
Main results expectedMay 2028
Study endsMay 2028
Registry record updatedJune 10, 2026
Trial IDNCT07638293 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older with acute respiratory failure who have been on HFNC for at least 24 hours and do not have contraindications listed in the criteria.

Probably not a fit

Patients with post-extubation HFNC, significant hypercapnia, DNI orders, terminal non-respiratory illness, or other listed contraindications may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares a protocolized weaning approach for high-flow nasal therapy (HFNC) against standard care in adults with acute respiratory failure. It aims to reduce variability in HFNC discontinuation and identify criteria that predict safe weaning, such as FiO2 ≤ 40% and a ROX index ≥ 9.2. The protocol focuses on standardized steps to taper HFNC while monitoring for signs of deterioration. The trial will measure respiratory outcomes and resource use to determine if structured weaning improves patient care and efficiency.

Why it matters

Potential benefit: If successful, the protocol could standardize HFNC discontinuation, potentially shortening hospital stays and reducing resource use without increasing respiratory complications.

How similar studies have gone: Previous research suggests that using FiO2 and ROX index metrics can help predict successful HFNC weaning, though standardized protocols are not yet widely adopted.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Presence of acute respiratory failure (ARF)
* Receiving HFNC treatment for ≥24 hours

Exclusion Criteria:

* Post-extubation HFNC use or tracheostomized patients
* Respiratory acidosis (pH \<7.35) or clinically significant acute hypercapnia (pCO₂ \>50 mmHg with worsening from baseline)
* Long-term home NIV or home CPAP use
* Do-not-intubate (DNI) orders precluding escalation to invasive mechanical ventilation
* Life expectancy ≤48-72 hours due to terminal non-respiratory disease
* Neurological impairment or deep sedation preventing safe HFNC use (e.g. coma or severe uncontrolled delirium)
* Technical contraindications to HFNC (i.e. facial trauma, maxillofacial surgery, severe nasal obstruction)
* Refusal to participate or inability to provide informed consent

Where it's running

  • Pulmonology Unit, ASST Santi Paolo e Carlo. Department of Health Sciences, University of Milan, Milan (Italy)
    Milan, Lombardy, Italy
    Recruiting
  • Pulmonology Unit, University Hospital "G. Rodolico-San Marco"
    Catania, Sicily, Italy
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.